Randomized Phase II Trial of Matrix Metalloproteinase Inhibitor COL-3 in AIDS-Related Kaposi's Sarcoma: An AIDS Malignancy Consortium Study
Bruce J. Dezube(Xilio Therapeutics (United States)), David M. Aboulafia(Virginia Mason Medical Center), Kenneth S. Bauer(University of Maryland, Baltimore), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Jeannette Y. Lee(University of Arkansas at Little Rock)
Cited by 170
Related Papers
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707
Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee.
|Journal of Clinical Oncology|1989|483
Preliminary Observations on the Effect of Recombinant Leukocyte a Interferon in Homosexual Men with Kaposi's Sarcoma
|New England Journal of Medicine|1983|358
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
|Nature Communications|2020|342